Nanobiotix (ENXTPA:NANO) Could Be 46% Undervalued As Melanoma Trial Results Land

Nanobiotix (ENXTPA:NANO) is back in focus after releasing updated Phase 1 data for JNJ-1900, or NBTXR3, in anti-PD-1-resistant advanced primary cutaneous melanoma treated with radiotherapy plus checkpoint inhibitors.

The fresh melanoma data has arrived at a time when Nanobiotix has already seen a sharp swing in sentiment, with a 49.71% 7-day share price return and a 48.53% year-to-date share price return, offset by a weaker 90-day share price return of 14.07% and a very large 3-year total shareholder return of about 4x. This signals strong longer term momentum even as shorter term moves remain volatile around the €28.22 level, and new clinical readouts reshape how investors think about both upside potential and clinical risk.

Capitalize on Nanobiotix's momentum shift by scanning a curated group of cancer and healthcare disruptors through the 123 healthcare AI stocks that may be setting up for their own breakout moves.

Nanobiotix now appears to be a high‑risk oncology specialist with real clinical traction, yet the share price has already risen sharply on recent data. Are you paying for a solid platform or overpaying for the story at €28.22?

Most Popular Narrative: 46% Undervalued

Nanobiotix is framed by the most followed narrative as materially undervalued, with a fair value of €52.20 against the €28.22 last close. This puts current enthusiasm for NBTXR3 and JNJ-1900 into the context of longer term projections and clinical inflection points.

The collaboration with Johnson & Johnson on NBTXR3, including a large Phase III in head and neck cancer and the CONVERGE Phase II in lung cancer, concentrates development on indications that management describes as sizable markets. These could influence future product revenue and milestone inflows if these programs progress.

Refocusing internal resources toward the Curadigm platform and other new drug classes, supported by four recent patent applications and ongoing IND enabling work, can shift the cost base toward programs the company fully owns. This may have a potential impact on long term gross margins and operating leverage.

See why 5 investors see Nanobiotix as 46% undervalued .

Result: Fair Value of €52.20 (UNDERVALUED)

Still, the bullish Nanobiotix story hinges on clinical execution and partner appetite, with setbacks in NANORAY 312 or limited Johnson & Johnson expansion both representing potential pressure points.

Find out about the key risks to this Nanobiotix narrative .

Next Steps

Sentiment around Nanobiotix is split, with strong enthusiasm and clear concerns sitting side by side. Move quickly and dig into both sides of the story by reviewing the 2 key rewards and 2 important warning signs